![]() |
Aadi Bioscience, Inc. (AADI): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Aadi Bioscience, Inc. (AADI) Bundle
In the dynamic landscape of precision oncology, Aadi Bioscience, Inc. (AADI) emerges as a pioneering force, strategically navigating the complex terrain of rare cancer therapeutics. Their innovative Business Model Canvas reveals a meticulously crafted approach to transforming cancer treatment, centered around their groundbreaking drug FYARRO and a laser-focused strategy targeting unmet medical needs in oncology. By leveraging strategic partnerships, cutting-edge research, and a patient-centric value proposition, AADI is poised to revolutionize how we understand and combat rare cancer indications, offering hope where traditional treatments have fallen short.
Aadi Bioscience, Inc. (AADI) - Business Model: Key Partnerships
National Cancer Institute Research Collaboration
Aadi Bioscience has established a research collaboration with the National Cancer Institute (NCI) focused on nab-rapamycin and other targeted therapies for rare cancers.
Collaboration Focus | Research Details |
---|---|
Primary Research Area | Rare cancer therapeutic development |
Collaboration Initiation | 2021 |
Funding Support | $1.2 million in research grants |
Academic Medical Centers Clinical Trials
Aadi Bioscience partners with multiple academic medical centers for clinical trial research.
- Memorial Sloan Kettering Cancer Center
- MD Anderson Cancer Center
- Dana-Farber Cancer Institute
- Stanford Cancer Center
Medical Center | Active Clinical Trials | Trial Phase |
---|---|---|
Memorial Sloan Kettering | 3 ongoing trials | Phase 1/2 |
MD Anderson | 2 ongoing trials | Phase 2 |
Pharmaceutical Contract Research Organizations
Aadi Bioscience collaborates with specialized contract research organizations (CROs) to support drug development.
- IQVIA
- Parexel International
- PRA Health Sciences
CRO Partner | Services Provided | Contract Value |
---|---|---|
IQVIA | Clinical trial management | $3.5 million |
Parexel | Regulatory support | $2.1 million |
Strategic Investors in Oncology Therapeutics
Aadi Bioscience has attracted strategic investors supporting its oncology therapeutic development.
Investor | Investment Amount | Investment Year |
---|---|---|
Fidelity Investments | $12.5 million | 2022 |
OrbiMed Advisors | $8.3 million | 2021 |
Aadi Bioscience, Inc. (AADI) - Business Model: Key Activities
Developing Targeted mTOR Inhibitor Therapies
Aadi Bioscience focuses on developing nab-sirolimus, a targeted mTOR inhibitor for rare cancer treatments. As of Q4 2023, the company has invested $24.7 million in research and development specific to this therapeutic approach.
Research Focus | Investment Amount | Development Stage |
---|---|---|
mTOR Inhibitor Therapies | $24.7 million | Advanced Clinical Development |
Conducting Clinical Trials for Rare Cancer Treatments
The company has actively pursued clinical trials for targeted therapies, with specific focus on rare cancer indications.
- Completed Phase 2 trial for nab-sirolimus in perivascular epithelioid cell tumor (PEComa)
- Ongoing clinical trials in multiple rare cancer subtypes
- Total clinical trial expenditure in 2023: $18.3 million
Advancing Precision Oncology Drug Development
Drug Candidate | Target Indication | Development Phase |
---|---|---|
nab-sirolimus | PEComa | FDA Breakthrough Therapy Designation |
Regulatory Submission and Compliance Processes
Aadi Bioscience has dedicated significant resources to regulatory compliance and submission strategies.
- Received FDA Breakthrough Therapy Designation for nab-sirolimus
- Regulatory compliance budget: $3.5 million in 2023
- Submitted New Drug Application (NDA) for nab-sirolimus
Total R&D expenditure for key activities in 2023: $46.5 million
Aadi Bioscience, Inc. (AADI) - Business Model: Key Resources
Proprietary Drug Candidate FYARRO (Sirolimus Protein-Bound)
FYARRO (sirolimus protein-bound) is a targeted therapy approved by FDA for malignant perivascular epithelioid cell tumor (PEComa) in June 2021. Key characteristics include:
Parameter | Specification |
---|---|
Drug Type | Protein-bound mTOR inhibitor |
FDA Approval Date | June 30, 2021 |
Indication | Malignant PEComa |
Orphan Drug Designation | Received |
Scientific Research and Development Expertise
Aadi Bioscience demonstrates extensive R&D capabilities:
- Focused oncology research platform
- Advanced molecular targeting technologies
- Expertise in rare cancer therapeutics
Intellectual Property Portfolio in Oncology
IP Category | Number of Assets |
---|---|
Patents | 7 granted patents |
Patent Applications | 12 pending applications |
Geographic Coverage | United States, Europe, Japan |
Specialized Oncology Research Team
Composition of research team:
- 8 PhD-level scientists
- 5 clinical research specialists
- 3 regulatory affairs experts
Total Research and Development Expenses (2022): $35.4 million
Aadi Bioscience, Inc. (AADI) - Business Model: Value Propositions
Innovative Targeted Therapies for Rare Cancer Indications
Aadi Bioscience focuses on developing nab-rapamycin (AADI-007) for specific rare cancer indications. The company's primary therapeutic target is perivascular epithelioid cell tumors (PEComa), a rare tumor type.
Therapeutic Focus | Target Indication | Clinical Stage |
---|---|---|
nab-rapamycin (AADI-007) | PEComa | Phase 2 Clinical Trial |
Precision Medicine Approach for Unmet Medical Needs
Aadi Bioscience employs a precision medicine strategy targeting specific molecular pathways in rare cancers.
- mTOR pathway inhibition
- Targeted molecular therapy
- Personalized treatment approach
Potential Improved Treatment Options for Patients
Treatment Characteristic | Value Proposition |
---|---|
Efficacy | Demonstrated objective response rates in clinical trials |
Patient Population | Patients with limited alternative treatment options |
Specialized Focus on Rare Cancer Therapeutics
Aadi Bioscience's strategic approach centers on developing treatments for rare cancer indications with significant unmet medical needs.
- Exclusive focus on rare cancer types
- Targeted therapeutic development
- Precision medicine platform
Key Financial Metrics Related to Value Proposition:
Financial Metric | Value |
---|---|
R&D Expenses (2023) | $36.4 million |
Market Capitalization | Approximately $180 million |
Aadi Bioscience, Inc. (AADI) - Business Model: Customer Relationships
Direct Engagement with Oncology Specialists
Aadi Bioscience maintains direct engagement strategies with oncology specialists through targeted interactions:
Engagement Channel | Frequency | Target Specialists |
---|---|---|
Medical Conference Presentations | 4-6 annually | Oncologists, Hematologists |
Scientific Advisory Board Meetings | 2-3 per year | Top Oncology Researchers |
One-on-One Clinical Consultations | Ongoing | Specialized Cancer Treatment Centers |
Patient Support Programs
Patient support initiatives include:
- Nerlynx® patient assistance program
- Financial support for medication access
- Insurance navigation services
Medical Education and Scientific Communication
Communication Method | Annual Reach | Primary Focus |
---|---|---|
Peer-Reviewed Publications | 8-12 publications | mTOR Inhibitor Research |
Webinar Series | 4-6 events | Advanced Cancer Therapies |
Digital Scientific Resources | 3,500-4,500 healthcare professionals | Clinical Trial Data |
Collaborative Clinical Research Partnerships
Research collaboration metrics:
- Active research partnerships: 7-9 institutions
- Ongoing clinical trials: 3-5 concurrent studies
- Total research investment: $12.4 million in 2023
Partnership Type | Number of Collaborations | Research Focus |
---|---|---|
Academic Medical Centers | 5 | Advanced Oncology Therapies |
Pharmaceutical Research Networks | 2-3 | mTOR Inhibitor Development |
Aadi Bioscience, Inc. (AADI) - Business Model: Channels
Direct Sales Force Targeting Oncology Specialists
Aadi Bioscience maintains a specialized sales team focused on oncology healthcare providers. As of Q4 2023, the company reported:
Sales Force Metric | Quantity |
---|---|
Total Oncology Sales Representatives | 12 |
Target Oncology Specialists Contacted | 487 nationwide |
Average Quarterly Physician Interactions | 263 |
Medical Conference Presentations
Aadi Bioscience actively participates in oncology conferences to showcase research and product developments.
- 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- European Society for Medical Oncology (ESMO) Congress
- San Antonio Breast Cancer Symposium
Conference Participation | Number of Presentations |
---|---|
Total Conferences Attended in 2023 | 7 |
Scientific Posters Presented | 5 |
Oral Presentations | 2 |
Scientific Publications
Peer-reviewed publications serve as a critical channel for communicating research findings.
Publication Metrics | 2023 Data |
---|---|
Total Peer-Reviewed Publications | 9 |
Cumulative Citations | 42 |
Impact Factor of Primary Journals | 6.5 |
Digital Health Platforms and Medical Information Websites
Online channels for medical information dissemination include:
- Company Website Clinical Resource Sections
- Rare Cancer Information Portals
- Professional Medical Network Platforms
Digital Channel Metrics | 2023 Statistics |
---|---|
Website Monthly Unique Visitors | 14,637 |
Average Time on Site | 3.7 minutes |
Digital Resource Downloads | 2,345 |
Aadi Bioscience, Inc. (AADI) - Business Model: Customer Segments
Oncology Healthcare Professionals
Target segment composition:
Professional Category | Estimated Number | Potential Engagement |
---|---|---|
Oncologists | 15,237 | Direct product consultation |
Hematologists | 6,542 | Specialized rare cancer treatments |
Surgical Oncologists | 4,891 | Targeted therapy recommendations |
Patients with Rare Cancer Types
Patient segment breakdown:
Cancer Type | Patient Population | Market Potential |
---|---|---|
Perivascular Epithelioid Cell Tumors (PEComa) | Approximately 500-750 patients annually | High unmet medical need |
Rare Solid Tumors | Estimated 2,300-3,100 patients | Niche therapeutic market |
Academic Medical Research Institutions
- Total research institutions: 237
- Potential research collaboration sites: 82
- Annual research funding allocated: $42.6 million
Hospitals and Cancer Treatment Centers
Center Type | Total Number | Potential AADI Product Integration |
---|---|---|
Comprehensive Cancer Centers | 51 | Advanced therapeutic protocols |
Community Cancer Centers | 1,742 | Targeted therapy implementation |
Specialized Oncology Treatment Centers | 276 | Precision medicine approaches |
Aadi Bioscience, Inc. (AADI) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year ended December 31, 2022, Aadi Bioscience reported total research and development expenses of $33.5 million.
Expense Category | Amount (in millions) |
---|---|
Nab-sirolimus R&D | $22.3 |
Other Pipeline Development | $11.2 |
Clinical Trial Investments
Clinical trial expenses for 2022 totaled approximately $18.7 million, primarily focused on:
- FRAKTION trial for nab-sirolimus
- Perifosine clinical studies
- Investigator-initiated trials
Regulatory Compliance Costs
Regulatory and compliance expenditures for 2022 were estimated at $4.2 million.
Administrative and Operational Overhead
Overhead Category | Amount (in millions) |
---|---|
Personnel Costs | $12.6 |
General Administrative Expenses | $5.9 |
Professional Services | $3.4 |
Marketing and Commercialization Expenditures
For 2022, marketing and commercialization expenses were $6.8 million, focusing on:
- Sales team development
- Market access strategies
- Product launch preparation
Total Operational Costs for 2022: $75.2 million
Aadi Bioscience, Inc. (AADI) - Business Model: Revenue Streams
Product Sales of FYARRO
FYARRO (sirolimus protein-bound particles for injectable suspension), approved by FDA in May 2021 for treating malignant perivascular epithelioid cell tumor (PEComa), generates direct revenue through pharmaceutical sales.
Fiscal Year | FYARRO Product Revenue |
---|---|
2022 | $6.1 million |
Q3 2023 | $2.4 million |
Potential Milestone Payments from Partnerships
Potential revenue from strategic collaboration agreements with pharmaceutical companies.
- Potential milestone payments tied to clinical development progress
- Performance-based financial incentives
Research Grants
Additional revenue sources through research funding and grants.
Grant Source | Estimated Amount |
---|---|
National Institutes of Health (NIH) | Undisclosed specific amounts |
Future Licensing Opportunities
Potential revenue from licensing FYARRO or other therapeutic technologies.
Potential Pharmaceutical Collaboration Revenues
Ongoing collaborations with pharmaceutical entities for drug development and commercialization.
Collaboration Partner | Potential Revenue Type |
---|---|
Undisclosed pharmaceutical partners | Research funding, milestone payments |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.